372 related articles for article (PubMed ID: 18957964)
21. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial.
Eck SL; Alavi JB; Alavi A; Davis A; Hackney D; Judy K; Mollman J; Phillips PC; Wheeldon EB; Wilson JM
Hum Gene Ther; 1996 Aug; 7(12):1465-82. PubMed ID: 8844206
[TBL] [Abstract][Full Text] [Related]
22. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD; Bag AK; Fiveash J; Kachurak K; Elsayed G; Chagoya G; Gessler F; Valdes PA; Madan-Swain A; Whitley R; Markert JM; Gillespie GY; Johnston JM; Friedman GK
Hum Gene Ther; 2020 Oct; 31(19-20):1132-1139. PubMed ID: 32657154
[TBL] [Abstract][Full Text] [Related]
23. Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy.
Whisenhunt TR; Rajneesh KF; Hackney JR; Markert JM
Oncolytic Virother; 2015; 4():33-8. PubMed ID: 27512668
[TBL] [Abstract][Full Text] [Related]
24. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Nakano K; Todo T; Zhao G; Yamaguchi K; Kuroki S; Cohen JB; Glorioso JC; Tanaka M
J Gene Med; 2005 May; 7(5):638-48. PubMed ID: 15754306
[TBL] [Abstract][Full Text] [Related]
25. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
26. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity.
Toda M; Rabkin SD; Kojima H; Martuza RL
Hum Gene Ther; 1999 Feb; 10(3):385-93. PubMed ID: 10048391
[TBL] [Abstract][Full Text] [Related]
27. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
[TBL] [Abstract][Full Text] [Related]
28. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer.
Bennett JJ; Delman KA; Burt BM; Mariotti A; Malhotra S; Zager J; Petrowsky H; Mastorides S; Federoff H; Fong Y
Cancer Gene Ther; 2002 Nov; 9(11):935-45. PubMed ID: 12386832
[TBL] [Abstract][Full Text] [Related]
29. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.
Kanai R; Tomita H; Shinoda A; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
Gene Ther; 2006 Jan; 13(2):106-16. PubMed ID: 16163378
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
31. Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain.
Radbill AE; Reddy AT; Markert JM; Wyss JM; Pike MM; Akella NS; Bharara N; Gillespie GY
J Neurovirol; 2007 Apr; 13(2):118-29. PubMed ID: 17505980
[TBL] [Abstract][Full Text] [Related]
32. Immuno-viral therapy as a new approach for the treatment of brain tumors.
Toda M
Drug News Perspect; 2003 May; 16(4):223-9. PubMed ID: 12942152
[TBL] [Abstract][Full Text] [Related]
33. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.
Rainov NG; Kramm CM; Banning U; Riemann D; Holzhausen HJ; Heidecke V; Burger KJ; Burkert W; Körholz D
Gene Ther; 2000 Nov; 7(21):1853-8. PubMed ID: 11110418
[TBL] [Abstract][Full Text] [Related]
34. [The biosafety of the HSV-TK/GCV gene therapy in five cases of recurrent glioblastoma multiforme].
Adachi N; Könü DL; Frei K; Yonekawa Y
No Shinkei Geka; 2000 Nov; 28(11):965-74. PubMed ID: 11127592
[TBL] [Abstract][Full Text] [Related]
35. Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.
Cinatl J; Michaelis M; Driever PH; Cinatl J; Hrabeta J; Suhan T; Doerr HW; Vogel JU
Neoplasia; 2004; 6(6):725-35. PubMed ID: 15720798
[TBL] [Abstract][Full Text] [Related]
36. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia enhances the replication of oncolytic herpes simplex virus.
Aghi MK; Liu TC; Rabkin S; Martuza RL
Mol Ther; 2009 Jan; 17(1):51-6. PubMed ID: 18957963
[TBL] [Abstract][Full Text] [Related]
38. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer.
Endo T; Toda M; Watanabe M; Iizuka Y; Kubota T; Kitajima M; Kawakami Y
Cancer Gene Ther; 2002 Feb; 9(2):142-8. PubMed ID: 11857031
[TBL] [Abstract][Full Text] [Related]
39. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.
Rampling R; Cruickshank G; Papanastassiou V; Nicoll J; Hadley D; Brennan D; Petty R; MacLean A; Harland J; McKie E; Mabbs R; Brown M
Gene Ther; 2000 May; 7(10):859-66. PubMed ID: 10845724
[TBL] [Abstract][Full Text] [Related]
40. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1.
Yazaki T; Manz HJ; Rabkin SD; Martuza RL
Cancer Res; 1995 Nov; 55(21):4752-6. PubMed ID: 7585498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
